|
Name |
Alloaureothin
|
| Molecular Formula | C22H23NO6 | |
| IUPAC Name* |
2-methoxy-3,5-dimethyl-6-[(2R,4Z)-4-[(Z)-2-methyl-3-(4-nitrophenyl)prop-2-enylidene]oxolan-2-yl]pyran-4-one
|
|
| SMILES |
CC1=C(OC(=C(C1=O)C)OC)[C@H]2C/C(=C/C(=C\C3=CC=C(C=C3)[N+](=O)[O-])/C)/CO2
|
|
| InChI |
InChI=1S/C22H23NO6/c1-13(9-16-5-7-18(8-6-16)23(25)26)10-17-11-19(28-12-17)21-14(2)20(24)15(3)22(27-4)29-21/h5-10,19H,11-12H2,1-4H3/b13-9-,17-10-/t19-/m1/s1
|
|
| InChIKey |
GQKXCBCSVYJUMI-WTEJLRIGSA-N
|
|
| Synonyms |
alloaureothin; 2-methoxy-3,5-dimethyl-6-[(2R,4Z)-4-[(Z)-2-methyl-3-(4-nitrophenyl)prop-2-enylidene]oxolan-2-yl]pyran-4-one; Alloarureothin; 11-cis aureothin; CHEMBL456466; SCHEMBL22346023; CHEBI:189211
|
|
| CAS | NA | |
| PubChem CID | 16724417 | |
| ChEMBL ID | CHEMBL456466 |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 397.4 | ALogp: | 3.6 |
| HBD: | 0 | HBA: | 6 |
| Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 90.6 | Aromatic Rings: | 3 |
| Heavy Atoms: | 29 | QED Weighted: | 0.514 |
| Caco-2 Permeability: | -4.551 | MDCK Permeability: | 0.00006430 |
| Pgp-inhibitor: | 0.016 | Pgp-substrate: | 0.004 |
| Human Intestinal Absorption (HIA): | 0.006 | 20% Bioavailability (F20%): | 0.002 |
| 30% Bioavailability (F30%): | 0.013 |
| Blood-Brain-Barrier Penetration (BBB): | 0.099 | Plasma Protein Binding (PPB): | 100.87% |
| Volume Distribution (VD): | 1.557 | Fu: | 1.17% |
| CYP1A2-inhibitor: | 0.844 | CYP1A2-substrate: | 0.924 |
| CYP2C19-inhibitor: | 0.904 | CYP2C19-substrate: | 0.435 |
| CYP2C9-inhibitor: | 0.874 | CYP2C9-substrate: | 0.018 |
| CYP2D6-inhibitor: | 0.32 | CYP2D6-substrate: | 0.113 |
| CYP3A4-inhibitor: | 0.811 | CYP3A4-substrate: | 0.619 |
| Clearance (CL): | 2.205 | Half-life (T1/2): | 0.143 |
| hERG Blockers: | 0.017 | Human Hepatotoxicity (H-HT): | 0.993 |
| Drug-inuced Liver Injury (DILI): | 0.977 | AMES Toxicity: | 0.974 |
| Rat Oral Acute Toxicity: | 0.122 | Maximum Recommended Daily Dose: | 0.332 |
| Skin Sensitization: | 0.823 | Carcinogencity: | 0.942 |
| Eye Corrosion: | 0.005 | Eye Irritation: | 0.054 |
| Respiratory Toxicity: | 0.583 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC004461 | ![]() |
1.000 | D05HFY | ![]() |
0.277 | ||
| ENC000034 | ![]() |
0.310 | D0I8DD | ![]() |
0.272 | ||
| ENC002787 | ![]() |
0.289 | D0A1DH | ![]() |
0.261 | ||
| ENC001224 | ![]() |
0.278 | D04OSE | ![]() |
0.246 | ||
| ENC005245 | ![]() |
0.267 | D0W2NM | ![]() |
0.241 | ||
| ENC005099 | ![]() |
0.260 | D06XZW | ![]() |
0.239 | ||
| ENC003428 | ![]() |
0.255 | D0XN1F | ![]() |
0.238 | ||
| ENC003859 | ![]() |
0.254 | D0T0KA | ![]() |
0.238 | ||
| ENC006146 | ![]() |
0.250 | D0CP4E | ![]() |
0.235 | ||
| ENC002836 | ![]() |
0.250 | D0S5CU | ![]() |
0.230 | ||